Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 1/20 | 0.46 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL338810 | 0.87 | LTA4H (0.70) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL7455134 | 0.85 | LTA4H (0.67) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL1464252 | 0.82 | — | — | |
| SCHEMBL8340210 | 0.80 | LTA4H (0.68) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL2463288 | 0.80 | KCNH2 (0.50) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL27709556 | 0.79 | CYP3A4 (0.60) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL29363583 | 0.78 | LTA4H (0.59) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL7058736 | 0.78 | LTA4H (0.59) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL12408419 | 0.78 | LTA4H (0.59) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 | |
| SCHEMBL14190036 | 0.78 | LTA4H (0.59) | LTA4HKCNH2CYP17A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338565-B2 | Macrocyclic compounds for inhibition of tumor necrosis factor alpha | ENSEMBLE THERAPEUTICS CORPORATION (US) | 2012-12-25 | — | — | US | claimed |
| EP-2350031-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | Ensemble Therapeutics Corporation (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE THERAPEUTICS CORPORATION | 2010-06-17 | — | — | US | claimed |
| WO-2010022249-A2 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | ENSEMBLE DISCOVERY CORPORATION (US) | 2010-02-25 | — | — | WO | claimed |
| EP-1633702-B1 | PROTEASE INHIBITORS | PROZYMEX AS (DK) | 2008-07-02 | — | — | EP | claimed |
| US-20070155803-A1 | Protease inhibitors | PROZYMEX A/S (DK) | 2007-07-05 | — | — | US | claimed |
| EP-1647545-A1 | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2006-04-19 | — | — | EP | claimed |
| EP-1633702-A1 | PROTEASE INHIBITORS | Prozymex A/S (DK) | 2006-03-15 | — | — | EP | claimed |
| EP-1005493-B1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2005-11-02 | — | — | EP | claimed |
| EP-1021186-B1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IkappaB-alpha | CV THERAPEUTICS INC (US) | 2005-06-29 | — | — | EP | claimed |
| EP-1005493-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2000-06-07 | — | — | EP | claimed |
| US-5977075-A | N-aroylamino acid amides as endothelin inhibitors | NOVARTIS AG (CH) | 1999-11-02 | — | — | US | claimed |
| CN-1231611-A | Puring inhibitors of cylin dependent kinase 2 and I'kappa'beta-'alpha' | CV THERAPEUTIC INC (US) | 1999-10-13 | — | — | CN | claimed |
| WO-1999026923-A1 | PARA-AMINOMETHYLARYL CARBOXAMIDE DERIVATIVES | MERCK & CO., INC. (US) | 1999-06-03 | — | — | WO | claimed |
| WO-1998045330-A1 | ANTIVIRAL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 1998-10-15 | — | — | WO | claimed |
| WO-1998005335-A9 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | — | 1998-05-28 | — | — | WO | claimed |
| WO-1998005335-A1 | PURINE INHIBITORS OF CYCLIN DEPENDENT KINASE 2 AND IλB-$g(a) | CV THERAPEUTICS, INC. (US) | 1998-02-12 | — | — | WO | claimed |
| EP-0821670-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | Novartis AG (CH) | 1998-02-04 | — | — | EP | claimed |
| EP-0795555-A1 | ANALGESICS | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1997-09-17 | — | — | EP | claimed |
| WO-1996033170-A1 | N-AROYLAMINO ACID AMIDES AS ENDOTHELIN INHIBITORS | NOVARITS AG (CH) | 1996-10-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152099-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF TUMOR NECROSIS FACTOR ALPHA | TNF, CD40, TNFRSF1A | LTA4H 98/4885KCNH2 3688/4885CYP17A1 478/4885 |
| US-20070155803-A1 | Protease inhibitors | DPP7, DPP9, DPP3 | LTA4H 1727/4885KCNH2 2276/4885CYP17A1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.